Furthermore, the radionuclide 64/67CuCl2 is currently being investigated as a PET imaging probe in nuclear medicine clinics for cancers, and MeCO-Sar (5-(8-methyl-3,6,10,13,16,19-hexaaza-bicyclo [6.6.6]icosan-1-ylamino)-5-oxopentanoic acid), conjugated to (Tyr3)-octreotate (64Cu-CuSarTATE), could be of interest for the detection and treatment of SSTR2-positive NETs in the future [73,74,75]. Here, SSTR2 is linked to cancer.